Letter to the Editor
Do we need a different strategy for HPV screening and vaccination in East Asia?
Shiho Miura,
Koji Matsumoto,
Akinori Oki,
Toyomi Satoh,
Hajime Tsunoda,
Toshiharu Yasugi,
Yuji Taketani,
Hiroyuki Yoshikawa,
Shiho Miura
Department of Obstetrics and Gynecology, University of Tokyo, Tokyo, Japan
Search for more papers by this authorCorresponding Author
Koji Matsumoto
Department of Obstetrics and Gynecology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Japan
Fax: +81-29-853-3072
Department of Obstetrics and Gynecology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba 305-8575, JapanSearch for more papers by this authorAkinori Oki
Department of Obstetrics and Gynecology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Japan
Search for more papers by this authorToyomi Satoh
Department of Obstetrics and Gynecology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Japan
Search for more papers by this authorHajime Tsunoda
Department of Obstetrics and Gynecology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Japan
Search for more papers by this authorToshiharu Yasugi
Department of Obstetrics and Gynecology, University of Tokyo, Tokyo, Japan
Search for more papers by this authorYuji Taketani
Department of Obstetrics and Gynecology, University of Tokyo, Tokyo, Japan
Search for more papers by this authorHiroyuki Yoshikawa
Department of Obstetrics and Gynecology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Japan
Search for more papers by this authorShiho Miura,
Koji Matsumoto,
Akinori Oki,
Toyomi Satoh,
Hajime Tsunoda,
Toshiharu Yasugi,
Yuji Taketani,
Hiroyuki Yoshikawa,
Shiho Miura
Department of Obstetrics and Gynecology, University of Tokyo, Tokyo, Japan
Search for more papers by this authorCorresponding Author
Koji Matsumoto
Department of Obstetrics and Gynecology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Japan
Fax: +81-29-853-3072
Department of Obstetrics and Gynecology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba 305-8575, JapanSearch for more papers by this authorAkinori Oki
Department of Obstetrics and Gynecology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Japan
Search for more papers by this authorToyomi Satoh
Department of Obstetrics and Gynecology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Japan
Search for more papers by this authorHajime Tsunoda
Department of Obstetrics and Gynecology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Japan
Search for more papers by this authorToshiharu Yasugi
Department of Obstetrics and Gynecology, University of Tokyo, Tokyo, Japan
Search for more papers by this authorYuji Taketani
Department of Obstetrics and Gynecology, University of Tokyo, Tokyo, Japan
Search for more papers by this authorHiroyuki Yoshikawa
Department of Obstetrics and Gynecology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Japan
Search for more papers by this author
References
- 1 Muñoz N, Bosch FX, Castellsagué X, Díaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004; 111: 278–85.
- 2 Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518–27.
- 3 Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: A meta-analysis. Br J Cancer 2003; 88: 63–73.
- 4 Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003; 89: 101–5.
- 5 Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757–65.
- 6 Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271–8.
- 7
Nakagawa S,
Yoshikawa H,
Onda T,
Kawana T,
Iwamoto A,
Taketani Y.
Type of human papillomavirus is related to clinical features of cervical carcinoma.
Cancer
1996;
78:
1935–41.
10.1002/(SICI)1097-0142(19961101)78:9<1935::AID-CNCR14>3.0.CO;2-Z CAS PubMed Web of Science® Google Scholar
- 8 Nakagawa S, Yoshikawa H, Kimura M, Kawana K, Matsumoto K, Onda T, Kino N, Yamada M, Yasugi T, Taketani Y. A possible involvement of aberrant expression of the FHIT gene in the carcinogenesis of squamous cell carcinoma of the uterine cervix. Br J Cancer 1999; 79: 589–94.
- 9 Yoshikawa H, Nagata C, Noda K, Nozawa S, Yajima A, Sekiya S, Sugimori H, Hirai Y, Kanazawa K, Sugase M, Shimizu H, Kawana T. Human papillomavirus infection and other risk factors for cervical intraepithelial neoplasia in Japan. Br J Cancer 1999; 80: 621–4.
- 10 Minaguchi T, Yoshikawa H, Nakagawa S, Yasugi T, Yano T, Iwase H, Mizutani K, Shiromizu K, Ohmi K, Watanabe Y, Noda K, Nishiu M et al. Association of PTEN mutation with HPV-negative adenocarcinoma of the uterine cervix. Cancer Lett 2004; 210: 57–62.
- 11 Nakagawa H, Sugano K, Fujii T, Kubushiro K, Tsukazaki K, Nozawa S. Frequent detection of human papilloma viruses in cervical dysplasia by PCR single-strand DNA-conformational polymorphism analysis. Anticancer Res 2002; 22: 1655–60.
- 12 Masumoto N, Fujii T, Ishikawa M, Mukai M, Saito M, Iwata T, Fukuchi T, Kubushiro K, Tsukazaki K, Nozawa S. Papanicolaou tests and molecular analyses using new fluid-based specimen collection technology in 3000 Japanese women. Br J Cancer 2003; 88: 1883–8.
- 13 Matsukura T, Sugase M. Human papillomavirus genomes in squamous cell carcinomas of the uterine cervix. Virology 2004; 324: 439–49.
- 14 Sasagawa T, Basha W, Yamazaki H, Inoue M. High-risk and multiple human papillomavirus infections associated with cervical abnormalities in Japanese women. Cancer Epidemiol Biomarkers Prev 2001; 10: 45–52.
- 15
Yoshino K,
Enomoto T,
Nakamura T,
Sun H,
Ozaki K,
Nakashima R,
Wada H,
Saitoh J,
Watanabe Y,
Noda K,
Murata Y.
FHIT alterations in cancerous and non-cancerous cervical epithelium.
Int J Cancer
2000;
85:
6–13.
10.1002/(SICI)1097-0215(20000101)85:1<6::AID-IJC2>3.0.CO;2-6 CAS PubMed Web of Science® Google Scholar
- 16 Tsuda H, Hashiguchi Y, Nishimura S, Kawamura N, Inoue T, Yamamoto K. Relationship between HPV typing and abnormality of G1 cell cycle regulators in cervical neoplasm. Gynecol Oncol 2003; 91: 476–85.
- 17 Miwa K, Miyamoto S, Kato H, Imamura T, Nishida M, Yoshikawa Y, Nagata Y, Wake N. The role of p53 inactivation in human cervical cell carcinoma development. Br J Cancer 1995; 71: 219–26.
- 18 Iwasaka T, Matsuo N, Yokoyama M, Uchiyama K, Fukuda H, Sugimori H. Prospective follow-up of Japanese women with cervical intraepithelial neoplasia and various human papillomavirus types. Int J Gynecol Obstet 1998; 62: 269–77.
- 19 Asato T, Maehama T, Nagai Y, Kanazawa K, Uezato H, Kariya K. A large case-control study of cervical cancer risk associated with human papillomavirus infection in Japan, by nucleotide sequencing-based genotyping. J Infect Dis 2004; 189: 1829–32.
- 20 Nagai Y, Maehama T, Asato T, Kanazawa K. Persistence of human papillomavirus infection after therapeutic conization for CIN 3: is it an alarm for disease recurrence? Gynecol Oncol 2000; 79: 294–9.
- 21 Lo KW, Wong YF, Chan MK, Li JC, Poon JS, Wang VW, Zhu SN, Zhang TM, He ZG, Wu QL, Li GD, Tam JS et al. Prevalence of human papillomavirus in cervical cancer: a multicenter study in China. Int J Cancer 2002; 100: 327–31.
- 22
Lai HC,
Sun CA,
Yu MH,
Chen HJ,
Liu HS,
Chu TY.
Favorable clinical outcome of cervical cancers infected with human papilloma virus type 58 and related types.
Int J Cancer
1999;
84:
553–7.
10.1002/(SICI)1097-0215(19991222)84:6<553::AID-IJC2>3.0.CO;2-4 CAS PubMed Web of Science® Google Scholar
- 23
Huang S,
Afonina I,
Miller BA,
Beckmann AM.
Human papillomavirus types 52 and 58 are prevalent in cervical cancers from Chinese women.
Int J Cancer
1997;
70:
408–11.
10.1002/(SICI)1097-0215(19970207)70:4<408::AID-IJC6>3.0.CO;2-# CAS PubMed Web of Science® Google Scholar
- 24
Lin QQ,
Yu SZ,
Qu W,
Cruz Y,
Burk RD.
Human papillomavirus types 52 and 58.
Int J Cancer
1998;
75:
484,485.
10.1002/(SICI)1097-0215(19980130)75:3<484::AID-IJC25>3.0.CO;2-7 CAS PubMed Web of Science® Google Scholar
- 25
Stephen AL,
Thompson CH,
Tattersall MH,
Cossart YE,
Rose BR.
Analysis of mutations in the URR and E6/E7 oncogenes of HPV 16 cervical cancer isolates from central China.
Int J Cancer
2000;
86:
695–701.
10.1002/(SICI)1097-0215(20000601)86:5<695::AID-IJC15>3.0.CO;2-C CAS PubMed Web of Science® Google Scholar
- 26 Hwang TS, Jeong JK, Park M, Han HS, Choi HK, Park TS. Detection and typing of HPV genotypes in various cervical lesions by HPV oligonucleotide microarray. Gynecol Oncol 2003; 90: 51–6.
- 27 Bulkmans NW, Bleeker MC, Berkhof J, Voorhorst FJ, Snijders PJ, Meijer CJ. Prevalence of types 16 and 33 is increased in high-risk human papillomavirus positive women with cervical intraepithelial neoplasia grade 2 or worse. Int J Cancer 2005; 117: 177–81.
Citing Literature
